The estimated 2-year overall survival (OS) was 81.9%, and event-free survival (EFS) was59.3%.Conclusion: High-dose chemotherapy followed by ASCT is an effective conditioning regimen in relapsed/refractorylymphoma patients who are undergoing ASCT.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Background/aim: High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has become thestandard approach for patients with relapsed/refractory Hodgkin’s lymphoma (HL) or non-Hodgkin’s lymphoma (NHL).In this study, we report the outcome of the mitoxantrone-melphalan conditioning regimen for lymphoma.Materials and methods: The study group included 53 patients who were relapsed/refractory HL (n = 14) and NHL (n =39) and received mitoxantrone and melphalan followed by ASCT.
📊
Key Findings & Data:The transplant regimen consisted of mitoxantrone (60mg/m2) and melphalan (180 mg/m2) followed by peripheral blood stem cell infusion (PBSC).Results: Prior to high-dose chemotherapy, 37.7% of the patients were in complete remission (CR) and 45.3% were inpartial remission (PR), and 17% had stable or progressive disease.
💡
Conclusion & Impact:The estimated 2-year overall survival (OS) was 81.9%, and event-free survival (EFS) was59.3%.Conclusion: High-dose chemotherapy followed by ASCT is an effective conditioning regimen in relapsed/refractorylymphoma patients who are undergoing ASCT.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Background/aim: High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has become thestandard approach for patients with relapsed/refractory Hodgkin’s lymphoma (HL) or non-Hodgkin’s lymphoma (NHL).In this study, we report the outcome of the mitoxantrone-melphalan conditioning regimen for lymphoma.Materials and methods: The study group included 53 patients who were relapsed/refractory HL (n = 14) and NHL (n =39) and received mitoxantrone and melphalan followed by ASCT. The transplant regimen consisted of mitoxantrone (60mg/m2) and melphalan (180 mg/m2) followed by peripheral blood stem cell infusion (PBSC).Results: Prior to high-dose chemotherapy, 37.7% of the patients were in complete remission (CR) and 45.3% were inpartial remission (PR), and 17% had stable or progressive disease. After high-dose chemotherapy and PBSC, 44 out of 51patients achieved CR (86.2%). CR was achieved in 24 out of 33 patients (72.7%) who were transplanted in a marginallyactive phase of the disease. At a median followup of 25.4 months (1.8–131.3 months) after ASCT, 13 patients relapsed/progressed and 8 patients died. The estimated 2-year overall survival (OS) was 81.9%, and event-free survival (EFS) was59.3%.Conclusion: High-dose chemotherapy followed by ASCT is an effective conditioning regimen in relapsed/refractorylymphoma patients who are undergoing ASCT.
🔖
Cite This Article
ÇİFTÇİLER, R., MALKAN, Ü. Y., ALADAĞ, E., DEMİROĞLU, H., BÜYÜKAŞIK, Y., OKAY, M., ÖZCEBE, O. İ., HAZNEDAROĞLU, İ. C., AKSU, S., SAYINALP, N., GÖKER, H. (2022). Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma. Turkish Journal of Medical Sciences, Cilt: 49 - Sayı: 4, 985–992. https://ajindex.com/articles/610232
Linch D, Goldstone A, McMillan A, Chopra R, Hudson GV et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. The Lancet 1993; 341 (8852): 1051-1054
Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S et al. Autologous transplantation as consolidation for aggressive non-Hodgkin’s lymphoma. New England Journal of Medicine 2013; 369 (18): 1681-1690. doi: 10.1056/NEJMoa1301077 3. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. New England Journal of Medicine 1995; 333 (23): 1540-1545. doi: 10.1056/nejm199512073332305 4. Mills W, Chopra R, McMillan A, Pearce R, Linch D et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. Journal of Clinical Oncology 1995; 13 (3): 588-595
Chen Y-B, Lane AA, Logan BR, Zhu X, Akpek G et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation 2015; 21 (6): 1046-1053
Isidori A, Piccaluga PP, Loscocco F, Guiducci B, Barulli S et al. High-dose therapy followed by stem cell transplantation in Hodgkin’s lymphoma: past and future. Expert Review of Hematology. 2013; 6 (4): 451-464. doi: 10.1586/17474086.2013.814451 7. Salar A, Sierra J, Gandarillas M, Caballero MD, Marin J et al. Autologous stem cell transplantation for clinically aggressive non-Hodgkin’s lymphoma: the role of preparative regimens. Bone Marrow Transplantation 2001; 27 (4): 405-412. doi: 10.1038/sj.bmt.1702795 8. Puig N, De La Rubia J, Remigia MJ, Jarque I, Martín G et al. Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leukemia & Lymphoma 2006; 47 (8): 1488-1494
Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation 2009; 15 (5): 523-536
Ulrickson M, Aldridge J, Kim HT, Hochberg EP, Hammerman P et al. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience. Biology of Blood an